Novartis, Microsoft Partner in Artificial Intelligence for Drug Development
By

By
Novartis has announced that it is collaborating with Microsoft to create the Novartis AI innovation lab and has selected Microsoft as its strategic artificial intelligence (AI) and data-science partner. Novartis…

BI Partners with Inflammasome Therapeutics to Develop Retinal Disease Therapies
By

By
Boehringer Ingelheim (BI) and Inflammasome Therapeutics, a developer of therapies for degenerative diseases, have entered into a co-development and license agreement to develop up to three therapies for patients with…

Sanofi, Abbott, Medtronic, Novo Nordisk Partner for Digital Solutions for Insulin Delivery
By

By
Sanofi and Novo Nordisk are partnering in separate deals for insulin delivery. Sanofi and Abbott are partnering to integrate glucose sensing and insulin-delivery technologies. Novo Nordisk and Medtronic are collaborating…

Sumitomo Dainippon Pharma, Roivant Sciences Announce Plans for $3-Billion Alliance
By

By
Sumitomo Dainippon Pharma, and Roivant Sciences, a New York-based healthcare company, have entered into a non-binding memorandum of understanding for a broad alliance to transfer ownership interests in five Roivant…

Sandoz, Polpharma Biologics Partner for Biosimilar of Biogen’s MS Drug Tysabri
By

By
Sandoz, the generics arm of Novartis, has partnered with Polpharma Biologics, a European developer and manufacturer of biosimilars and biologic drugs, for global commercialization of a proposed biosimilar of Biogen’s…

Celgene, Immatics Form Collaboration for Adoptive Cell Therapies
By

By
Celgene and Immatics Biotechnologies, a clinical-stage pharmaceutical company developing T-cell redirecting cancer immunotherapies, have formed a strategic collaboration and option agreement to develop adoptive cell therapies targeting multiple cancers. Under…

Gilead and Galapagos Close $5.0-Billion Research and Development Deal
By

By
Gilead Sciences and Galapagos NV, a Mechelen, Belgium-based small-molecule drug company, have closed their previously announced global research and development collaboration agreement in a deal worth more than $5.0 billion.…

Merck & Co. Enters Collaboration with Themis Bioscience for Vaccine Candidates
By

By
MSD, known as Merck & Co., Inc. in the U.S. and Canada, has agreed to a collaboration with Themis Biosciences, a developer of therapies for infectious diseases and cancer, for…

Global Pharma Briefs: News from Europe, Asia and the Middle East
By

By
A roundup of developments and the latest news from China (Cipla, Jiangsu Acebright, Sun Pharma), Europe (European Medicines Agency, Swissmedic), India (Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, Natco Pharma), Israel (Mapi…

Roche Partners with Enable Injections for Wearable Infusion Devices
By

By
Roche’s Genentech and Enable Injections, a developer and manufacturer of investigational wearable infusion devices for combination products, have partnered for multiple programs using Enable’s en-Fuse platform, a drug-delivery device designed…